What changed for Oesophageal Cancer
A plain English summary of what recently moved in the public data Voxsanity tracks for Oesophageal Cancer. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials recruiting at Australian sites 11 to 10 (-1)
- Trials on record 1,908 to 1,901 (-7)
Newly subsidised on the PBS
No medicines were newly subsidised on the PBS for Oesophageal Cancer in July 2026. Voxsanity tracks 4 PBS-subsidised medicines for this condition; none of them was listed for the first time this month.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
The 30 most recent of 52 trials tracked for Oesophageal Cancer that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT04540211 · results posted 9 April 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT04540211) enrolled 461 people in total — 232 in the placebo group (placebo plus chemotherapy drugs paclitaxel and carboplatin, referred to as PC) and 229 in the combination group (atezolizumab and tiragolumab plus the same chemotherapy). The trial was primarily measuring two things: how long participants went without their cancer growing or spreading (called progression-free survival, or PFS), and how long participants lived overall (called overall survival, or OS). It is worth noting that no participants were recorded as...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03611309 · results posted 8 January 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT03611309) enrolled 359 people in total — 182 in a group where patients were cared for jointly by their surgeon and a palliative care team, and 177 in a group managed by their surgeon alone. The trial was looking at whether adding a palliative care team alongside the surgeon made a difference to patients' quality of life, mood, spiritual wellbeing, symptom burden, understanding of their prognosis, and survival over six months, all measured after cancer-related surgery. The reported data shows that for the main outcome — qu...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03641313 · results posted 8 July 2025
According to the results reported on ClinicalTrials.gov, this trial looked at a combination of two medicines — irinotecan and M6620 — given to people with a type of cancer being studied in a single treatment group. A total of 17 people enrolled in the trial, 12 completed it, and 5 did not finish. The trial's main goal was to measure the "objective response rate" — that is, how many participants' tumours either shrank significantly (a "partial response") or disappeared completely (a "complete response") according to standard imaging-based criteria. The reported data shows that, out of all 17 p...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04752358 · results posted 4 September 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled a very small number of participants — two people with oesophageal cancer and one person with oesophagogastric junction cancer (where the oesophagus meets the stomach), giving a total of three participants. The trial was investigating a T-cell based treatment and was designed to measure how well tumours responded to the treatment, how long any response lasted, and what unwanted medical events (called adverse events) occurred during the study. Notably, none of the three participants completed the study. The reported da...
-
NCT03430843 · results posted 29 December 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT03430843) enrolled 256 participants in each group — one group received a medicine called tislelizumab, and the other received chemotherapy chosen by their doctor (referred to as "investigator chosen chemotherapy"). The trial was measuring how long participants lived overall, how long they lived before their cancer got worse, and how many participants' tumours shrank or disappeared. Results were looked at for all participants combined (the "ITT" group) and separately for a smaller group whose tumours tested positive for a p...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02609425 · results posted 24 November 2023
According to the results reported on ClinicalTrials.gov, this trial enrolled 30 participants, and all 30 completed the study with none dropping out. The trial was looking at a specific type of surgical suture (stitch) called Stratafix, used during an oesophagectomy — an operation to remove part or all of the oesophagus (the tube connecting the throat to the stomach). The study was measuring two things after surgery: whether a leak occurred at the join where the oesophagus was reconnected (called an anastomotic leak), and whether that join later became too narrow, causing a blockage (called an...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03783442 · results posted 7 November 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT03783442) enrolled 649 people — 326 in the tislelizumab plus chemotherapy group and 323 in the placebo plus chemotherapy group. The trial was measuring outcomes for people with oesophageal cancer. The main thing researchers were tracking was **overall survival** — that is, how long participants lived from the time they joined the trial. Several secondary measures were also tracked, including how long it took for the disease to get worse (progression-free survival), how many participants showed a measurable reduction in the...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03709706 · results posted 7 August 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT03709706) enrolled 34 people across two groups: 20 participants received a treatment called lete-cel on its own (Arm A), and 14 received lete-cel combined with another medicine called pembrolizumab (Arm C). The trial was studying a type of cell therapy for cancer, and it was primarily measuring unwanted medical events (called adverse events) that occurred after treatment, as well as whether participants' tumours shrank or disappeared (called the overall response rate). Only a smaller subgroup — 7 people in Arm A and 6 in A...
-
NCT02530437 · results posted 10 July 2023
According to the results reported on ClinicalTrials.gov, this was a Phase 1B clinical trial that enrolled 7 participants. All 7 completed the study. The trial was looking at a combination treatment involving a drug called taladegib given together with two chemotherapy medicines (paclitaxel and carboplatin) and radiation therapy, in people with oesophageal cancer. The main things being measured were how often certain side effects occurred that were serious enough to limit the dose (called "dose-limiting toxicities"), and whether participants had no detectable cancer remaining in the tissue remo...
-
NCT02965976 · results posted 16 February 2023
According to the results reported on ClinicalTrials.gov, this trial looked at whether injecting Botulinum Toxin Type A (commonly known as Botox) during oesophageal surgery (removal of the oesophagus, or food pipe) might affect a condition called delayed gastric emptying — where the stomach is slow to move food through after surgery. A total of 32 people took part: 15 were in the group that received the Botox injection alongside their surgery, and 17 had surgery alone. Of those who started, 13 in the Botox group and all 17 in the surgery-only group completed the study. The reported data shows...
-
NCT03814824 · results posted 7 October 2022
According to the results reported on ClinicalTrials.gov, this trial enrolled 133 people in total — 67 in one group and 66 in the other. It was a crossover study, meaning each participant experienced both approaches being compared: a type of scan called VLE (Volumetric Laser Endomicroscopy) used on its own, and VLE used together with a feature called IRIS (Intelligent Real-time Image Segmentation). The trial was measuring how long it took doctors to review and interpret the scan images, using that time as a way to gauge how easy the images were to read. It also looked at how many participants h...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03417570 · results posted 29 July 2022
According to the results reported on ClinicalTrials.gov, this trial enrolled 100 people in total — 50 in each group. All 100 participants completed the study with no dropouts. The trial was comparing two versions of the same stomach and oesophagus camera examination (called an endoscopy): one performed with a small plastic cap fitted to the tip of the camera, and one performed without that cap. Each participant underwent both versions of the procedure. The main thing being measured was how many participants had abnormal tissue changes in their oesophagus (known as Barrett's oesophagus) that we...
-
NCT02872116 · results posted 28 June 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT02872116) enrolled a total of 2,031 participants across three treatment groups: one group received nivolumab (an immunotherapy medicine) combined with chemotherapy (789 people), one group received chemotherapy alone (833 people), and one group received nivolumab combined with another immunotherapy called ipilimumab (409 people). The trial was studying treatments for gastric (stomach) and related cancers. The main things being measured were how long participants lived overall (called "overall survival"), and how long they w...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03335813 · results posted 9 June 2022
According to the results reported on ClinicalTrials.gov, seven people took part in this trial, which tested a type of internal radiation treatment called brachytherapy, delivered using a multichannel balloon applicator placed inside the lung. Six participants completed the trial and one did not. The trial was measuring how precisely and fully the radiation dose could be delivered to the tumour, and how much radiation reached nearby organs such as the heart, aorta (the main blood vessel from the heart), and the airway (bronchus). The reported data shows that, on average, 90% of the tumour volu...
-
NCT02971956 · results posted 8 April 2022
According to the results reported on ClinicalTrials.gov, this trial enrolled 49 participants, all of whom completed the study. Every participant received pembrolizumab, an immunotherapy drug. The trial was measuring how often the tumours responded to treatment, how long participants went without their disease getting worse, how long participants lived overall, and how many experienced serious side effects linked to the treatment. The reported data shows that the overall response rate — meaning the proportion of participants whose tumours either disappeared completely or shrank by a meaningful...
-
NCT03143153 · results posted 2 March 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT03143153) enrolled 970 people across three treatment groups: 325 received a combination of nivolumab and ipilimumab (two immunotherapy medicines), 321 received nivolumab combined with chemotherapy, and 324 received chemotherapy alone. The trial was measuring two main things: how long participants lived overall (called "overall survival"), and how long they lived without their cancer growing or spreading (called "progression-free survival," meaning the time before the disease got worse or the person passed away). These main...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01900691 · results posted 23 February 2022
According to the results reported on ClinicalTrials.gov, this trial enrolled 130 people who received an Evolution® Esophageal Stent — a type of mesh tube placed in the oesophagus (the food pipe). The trial was looking at two main things: first, whether the stent could be successfully removed using a camera procedure (endoscopy), and second, whether people who had a non-cancerous (benign) condition in their oesophagus reported an improvement in their swallowing difficulties or were able to eat and drink by mouth again. A total of 111 participants completed the study, while 19 did not. The repo...
-
NCT03245736 · results posted 4 November 2021
According to the results reported on ClinicalTrials.gov, this trial enrolled 5 participants, all of whom received a drug called tisotumab vedotin. The trial was an extension study, meaning participants had already taken part in an earlier related trial. The main thing the trial was set up to measure was how many participants experienced what are called "treatment emergent adverse events" — that is, any unwanted medical occurrences that happened after starting the study drug or that got worse during the treatment period. None of the 5 participants completed the study. The reported data shows t...
-
NCT02625610 · results posted 4 November 2021
According to the results reported on ClinicalTrials.gov, this trial (NCT02625610) enrolled 499 people — 250 in the chemotherapy plus best supportive care group and 249 in the avelumab group. The trial was measuring how long participants lived overall, how long they lived without their disease getting worse, how their tumours responded to treatment, and how they rated their own quality of life over time. The reported data shows that for the primary measure — overall survival, meaning the time from the start of the trial until death from any cause — the chemotherapy plus best supportive care gr...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02743494 · results posted 22 June 2021
According to the results reported on ClinicalTrials.gov, this trial (NCT02743494) enrolled 532 people in the nivolumab group and 262 people in the placebo group — a total of 794 participants. The trial was measuring two main things: how long people went without their disease coming back after surgery (called "disease-free survival"), and how long people lived overall (called "overall survival"). Participants were randomly assigned to receive either nivolumab or a placebo (an inactive treatment used for comparison). The reported data shows that, on average, people in the nivolumab group went a...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01196390 · results posted 4 May 2021
According to the results reported on ClinicalTrials.gov, this trial enrolled 203 people with oesophageal (food pipe) cancer whose tumours tested positive for a protein called HER2. Participants were randomly placed into one of two groups: one group received standard chemoradiation (chemotherapy combined with radiation) plus a medicine called trastuzumab, and the other received chemoradiation alone. The trial was primarily looking at "disease-free survival" — that is, how long participants went without their cancer returning, spreading, or dying from any cause. The reported data shows that, on...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01217060 · results posted 13 April 2021
According to the results reported on ClinicalTrials.gov, this trial (NCT01217060) enrolled 4 participants, all of whom received the same treatment: a combination of two chemotherapy drugs (docetaxel and 5-FU), radiation therapy, and then surgery. This approach is sometimes called "trimodality" treatment. The trial was designed to look at outcomes for people with an early-stage cancer of the oesophagus (the tube that carries food from the mouth to the stomach) or the junction where the oesophagus meets the stomach. Of the 4 people who started the trial, 3 completed it and 1 did not. The report...
-
NCT03449030 · results posted 22 March 2021
According to the results reported on ClinicalTrials.gov, this trial (NCT03449030) tested a drug called TAK-164 in 31 adults in total. Participants were divided into ten groups, each receiving a different dose of TAK-164, ranging from very low to higher amounts. The trial was an early-stage study designed to find out how different doses of the drug affected participants and to identify what are called "dose-limiting toxicities" — that is, side effects serious enough at a given dose to limit how much could safely be given. No participant was recorded as having completed the study in the formal s...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01913639 · results posted 15 May 2020
According to the results reported on ClinicalTrials.gov, this trial enrolled 39 people, all of whom received a combination treatment of FOLFOX (a chemotherapy regimen) plus Regorafenib (a targeted cancer medicine). The trial was measuring how long participants went without their disease getting worse (called progression-free survival), how long participants lived overall, and how many participants' tumours shrank or disappeared during treatment. Thirty-six people completed the trial, and three did not. The reported data shows that 53% of participants were free from their disease getting worse...
-
NCT01439594 · results posted 22 November 2019
According to the results reported on ClinicalTrials.gov, this trial (NCT01439594) enrolled 17 participants, all of whom completed the study with no drop-outs. The trial was looking at whether a particular imaging technique called OFDI (Optical Frequency Domain Imaging) could be used to take clear internal images of tissue and compare those images to standard biopsy samples taken during a procedure involving radiofrequency ablation — a technique that uses heat to treat tissue. The goal was to see if the imaging approach was practical and could produce usable pictures. The reported data shows t...
-
NCT01498289 · results posted 29 August 2019
According to the results reported on ClinicalTrials.gov, this trial enrolled 202 people in total — 98 in Arm I (a chemotherapy regimen called FOLFOX) and 104 in Arm II (referred to as "IT"). The trial was looking at how long participants went without their cancer getting worse (called progression-free survival, or PFS) and how long they lived overall (overall survival). Participants were also grouped by their levels of a protein called ERCC1, which the researchers were interested in as a potential marker that might relate to how people respond to treatment. The reported data shows that among...
-
NCT01477177 · results posted 15 May 2019
According to the results reported on ClinicalTrials.gov, this trial involved 4 participants, all of whom were in a single group receiving a treatment called the "Polar Wand." All 4 participants who started the trial completed it. The trial was looking at a condition called Barrett's oesophagus — a change in the lining of the food pipe that can sometimes be detected during a scope examination. The study aimed to measure whether the Polar Wand treatment changed the appearance and tissue classification of Barrett's oesophagus over time, as well as the length of the affected area in the food pipe....
-
NCT02234180 · results posted 17 October 2018
According to the results reported on ClinicalTrials.gov, this trial (NCT02234180) enrolled a very small number of participants — just 3 people in total. Two were assigned to receive regorafenib (the study drug) and one received a placebo (a dummy treatment with no active ingredient). The trial was measuring how long people remained free of their disease returning after treatment (called "disease-free survival"), as well as tracking side effects and how long participants lived overall. The reported data shows that, across all participants combined, the median disease-free survival — meaning th...
-
NCT01446874 · results posted 12 June 2018
According to the results reported on ClinicalTrials.gov, this trial looked at whether a toothbrushing routine before (and after) major chest surgery might be related to rates of lung infection (pneumonia) in the 30 days following the operation. A total of 150 people started the trial across three groups: 20 in an early pilot group who only followed a pre-surgery brushing routine, 50 who were having oesophageal (food-pipe) removal surgery and followed both pre- and post-surgery brushing routines, and 80 who were having lung removal surgery and also followed both routines. Of those who started,...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02392377 · results posted 13 February 2018
According to the results reported on ClinicalTrials.gov, this trial (NCT02392377) involved two treatment groups: one receiving paclitaxel, carboplatin, radiation therapy, and surgery (Arm I), and one receiving a combination chemotherapy regimen, radiation therapy, and surgery (Arm II). The trial was designed to look at biological markers — specifically, patterns of gene activity and tiny molecules called microRNAs — in tumour samples, to see whether those patterns could be linked to how well patients responded to their treatment. Response was measured using a type of body scan called an FDG-PE...
See all 52 reported results for Oesophageal Cancer
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, research into oesophageal cancer is receiving a substantial level of public investment from the United States, and encouragingly, that investment has been growing year on year. This rising trend suggests that oesophageal cancer is being taken seriously as a research priority by major public funders. For patients, this kind of sustained and increasing financial commit...
See the full Oesophageal Cancer page
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.